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Obliterative bronchiolitis (OB) develops insidiously in nearly half of all lung transplant 
recipients. Although typically preceded by a CD8
 
 
 
 T cell–rich lymphocytic bronchitis, it 
remains unresponsive to conventional immunosuppression. Using an airflow permissive 
model to study the role of gases flowing over the transplanted airway, it is shown that 
prolonged inhalation of sublethal doses of carbon monoxide (CO), but not nitric oxide (NO), 
obliterate the appearance of the obstructive airway lesion. Induction of the enzyme 
responsible for the synthesis of CO, heme oxygenase (Hmox) 1, increased carboxyhemoglobin 
levels and suppressed lymphocytic bronchitis and airway luminal occlusion after transplantation. 
In contrast, zinc protoporphyrin IX, a competitive inhibitor of Hmox, increased airway 
luminal occlusion. Compared with wild-type allografts, expression of inducible NO synthase 
(iNOS), which promotes the influx of cytoeffector leukocytes and airway graft rejection, 
was strikingly reduced by either enhanced expression of Hmox-1 or exogenous CO. Hmox-1/CO 
decreased nuclear factor (NF)-
 
 
 
B binding activity to the iNOS promoter region and iNOS 
expression. Inhibition of soluble guanylate cyclase did not interfere with the ability of CO to 
suppress OB, implicating a cyclic guanosine 3
 
 
 
,5
 
 
 
-monophosphate–independent mechanism 
through which CO suppresses NF-
 
 
 
B, iNOS transcription, and OB. Prolonged CO inhalation 
represents a new immunosuppresive strategy to prevent OB.
 
Lung transplantation across an allogeneic barrier
often provokes a severe inflammatory response,
characterized by a massive lymphocytic influx
into the graft. Although vascular structures can
be targets of chronic rejection, as in all trans-
planted solid organs, the pronounced involve-
ment of airway structures represents a unique
and clinically devastating feature in chronically
rejecting transplanted lungs (1). The trans-
planted airway resides in a unique topographic
interface and is subjected to the continuous
topical exposure of biological gases both pro-
duced within the organism and inhaled from
the external environment. Synthesis of NO, a
diatomic gas with pleiotropic immune and
nonimmune functions, is increased during air-
way rejection, where it has been shown to ex-
acerbate lymphocytic bronchitis and airway
obliteration (2). Expression of the inducible
heme oxygenase (Hmox) enzyme responsible
for synthesis of a related diatomic gas, CO, is
also increased in human lung transplants with
acute cellular rejection and obliterative bron-
chiolitis (OB; reference 3). In contrast to the
activity of inducible NO synthase (iNOS) as a
potent immune effector mechanism, Hmox-1
has been shown to possess antiinflammatory
properties. As heme oxygenases are the rate-
limiting enzymes (4, 5) in the synthesis of the
endogenous gaseous molecule CO as a byprod-
uct of heme catabolism, it has been suggested
that CO derived from this catalytic process may
have important antiinflammatory functions (6,
7). The strong induction of Hmox during lung
transplant rejection leads to the hypothesis that
endogenous expression of Hmox-1 and deriva-
tive CO may serve as countervailing mecha-
nisms to limit tissue inflammation and injury
induced by iNOS in the setting of airway
transplant rejection.
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To test this hypothesis, a new model of transplantation-
associated obliterative airway disease was studied in mice
lacking the 
 
Hmox-1
 
 gene, or those in which Hmox-1 ex-
pression was enhanced. Mice were subjected to prolonged
inhalation of either CO or NO in the presence or absence of
various pharmacological inhibitors of downstream signaling
cascades. Data reveal that endogenous Hmox-1 expression/
CO production provide critical and counterbalancing pro-
tection against the OB induced by enhanced iNOS expres-
sion in the airway allografts. Additional data suggest that sup-
pression of NF-
 
 
 
B nuclear translocation by CO results in
down-regulation of iNOS expression and consequent sup-
pression of OB development.
 
RESULTS
Morphometric analysis of graft narrowing
 
Airway transplantation across an allogeneic barrier in an air-
flow-permissive transplant model results in significant lumi-
nal narrowing, which is not seen in the same model when
the transplanted graft is isogeneic with the recipient. Charac-
teristic thickening of the epithelial and subepithelial layers
lead to partial concentric graft luminal occlusion (47 
 
 
 
 4%
for wild-type allografts vs. 16 
 
 
 
 1% for isografts; P 
 
  
 
0.05;
Fig. 1). To determine whether induction of Hmox-1 can al-
ter this natural history, cobalt protoporphyrin IX (CoPP)
was administered to donors and recipients. This treatment
regimen was associated with a strong induction of Hmox-1
protein (see Fig. 3 i and Fig. 4 C) and mRNA (see Fig. 4 A)
in the transplanted grafts. CoPP treatment significantly re-
duced luminal occlusion (P 
 
  
 
0.05; Fig. 1). In contrast to
CoPP, treatment with zinc protoporphyrin IX (ZnPP),
which acts as a competitive inhibitor of Hmox activity, re-
sulted in a substantial amount of luminal occlusion (50 
 
 
 
2%). Preliminary experiments indicated that carboxyhemo-
globin (COHb) levels were 17 
 
 
 
 1% in mice (
 
n
 
 
 
  
 
5)
exposed to 250 ppm CO for 2 wk. When Hmox-1
 
 
 
/
 
 
 
 al-
lograft recipients were placed in a similar (250 ppm) CO-
rich environment for 2 wk after transplantation, graft lumi-
nal occlusion was diminished to a similar degree as that seen
after Hmox-1 induction with CoPP. The suppressive effect
of CO on airway luminal obliteration was not seen when
CO was given solely to the donor animal for 24 h before the
tracheal harvest (see Fig. 2 C).
To further evaluate the role of endogenous expression
on graft luminal obliteration, the next series of experiments
was performed using donor trachea, from mice lacking the
 
Hmox-1
 
 gene, transplanted into allogeneic Hmox-1
 
 
 
/
 
 
 
 re-
cipients. In these experiments, a significant increase in lumi-
nal occlusion was observed (69 
 
 
 
 6%) compared with that
seen in Hmox-1
 
 
 
/
 
 
 
 to Hmox-1
 
 
 
/
 
 
 
 allotransplants (47 
 
 
 
4%; P 
 
  
 
0.05). Inhalation of 250 ppm CO for 2 wk signifi-
cantly rescued the Hmox-1–null transplants from the devel-
Figure 1. Graft luminal narrowing at 3 wk after transplantation. 
Representative sections and morphometric analysis of sections for each of 
the indicated conditions are shown. Allograft recipients were all Hmox-1 / ; 
donor tracheas were obtained from either Hmox-1 /  or Hmox-1 /  mice 
as indicated in the figure.  Hmox-1 /  isografts are shown for compari-
son.  The following conditions were examined: an Hmox-1–inducer (CoPP); 
an Hmox-inhibitor (ZnPP); exogenous CO (250 ppm) or NO (20 ppm) 
inhalation for 2 wk after transplantation; and pharmacological inhibitors 
(L-NIL to inhibit iNOS or ODQ to inhibit sGC).  For certain experiments, sul-
fasalazine, a specific inhibitor of NF- B (references 36, 37), was given to 
Hmox /  graft–recipient mice as a drinking water supplement (130 mg/kg/d) 
for 3 wk after transplantation.  5–10 transplants were performed for each 
group. *,  P   0.05 versus Hmox-1 / ;  #,  P   0.05 versus Hmox-1 /  
allografts.  Representative histological sections are shown under each bar. 
Data are mean   SEM. 
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opment of airway luminal obliteration (35 
 
 
 
 2%; P 
 
  
 
0.05
vs. Hmox-1
 
 
 
/
 
 
 
 allografts in the absence of inhaled CO).
In a recent study using the identical airway transplant
model system, induction of iNOS was shown to be a patho-
logical mediator of airway rejection, the blockade of which
could reduce airway luminal obliteration (2). In the current
experiments, coadministration of the iNOS blocker N
 
6
 
-(1-
iminoethyl)-
 
L
 
-lysine dihydrochloride
 
 
 
(L-NIL) with inhaled
CO (in either Hmox-1
 
 
 
/
 
 
 
 or Hmox-1
 
 
 
/
 
 
 
 transplants) did
not further reduce luminal obliteration compared with con-
ditions in which CO was administered alone (Fig. 1). When
inhaled NO was administered to Hmox-1
 
 
 
/
 
 
 
 allograft recip-
ients at a dose that results in comparable soluble guanylate
cyclase (sGC) activation (20 ppm; reference 8) for 2 wk after
transplantation, it became clear that prolonged NO exposure
not only did not reduce luminal obliteration but actually ex-
acerbated it (56 
 
 
 
 3%; P 
 
  
 
0.05 vs. Hmox-1
 
 
 
/
 
 
 
 allografts).
This is in stark contrast to the beneficial vascular effects of
inhaled NO seen shortly after lung transplantation (9). Col-
lectively, these data indicate that NO and CO have distinct
biological profiles in this allograft model of OB. To test the
mechanistic link between Hmox-1, CO, and iNOS induc-
tion, we studied whether inhibition of NOS2 (iNOS) activ-
ity might abrogate luminal obliteration, particularly in
Hmox-1–null allografts (Fig. 2 A). In a completely distinct
cohort of animals from those shown in Fig. 1 A, isografts or
allografts were implanted and luminal obliteration assessed at
1 wk without immunosuppression. L-NIL brought luminal
obliteration in Hmox-1
 
 
 
/
 
 
 
 mice down to the baseline levels
seen in Hmox-1
 
 
 
/
 
 
 
 allografts. The overall diminution of lu-
minal obliteration in WT allografts is similar to that which
we have previously observed (2).
The next question, which was experimentally addressed,
was whether the site of Hmox-1 expression was important
in the observed protection against luminal narrowing. This
question is particularly relevant because iNOS expressed in
airway graft tissue has no apparent effect on airway rejection,
whereas recipient leukocyte-derived iNOS plays a critical
exacerbating role (2). The situation appears to be quite dif-
Figure 2. Graft luminal occlusion in response to the presence/absence 
of the Hmox-1 gene, with or without iNOS inhibition or donor-inhaled 
CO. (A) Effect of iNOS inhibition in the recipient (5mg/kg/d L-NIL) on graft 
luminal occlusion. Six transplants were performed for each experiment. 
*, P   0.05. (B) Effect of epithelial- versus leukocyte-derived Hmox-1 (HO-
1) on graft luminal narrowing. Genotypes of donors and recipients were 
either Hmox-1 /  or Hmox-1 / , as indicated. Genotypes that are under-
lined represent the B10.A strain background, whereas those that are not 
underlined represent the 129Sv   BALB/c strain background. Note that 
the leftmost two bars present the same data as are shown in A, repeated 
here to facilitate comparison (*, P   0.05; n   8 for the right and right-
most bars). (C) Effect of a 250-ppm CO dose for 24 h given solely to donor 
mice before the airway transplantation. The number of transplants per-
formed for each experiment were as follows: 4 (left), 11 (middle), and 
5 (right). Data are mean   SEM.
Figure 3. Immunohistochemical detection of graft-infiltrating 
T cells and the enzymes Hmox-1 and iNOS. Immunohistochemical 
staining of the pan–T cell marker CD3 (a–f, brown), as well as Hmox-1 
(HO-1; g–l, brown) and iNOS (m–r, red), in adjacent serial sections from 
airway grafts at 3 wk after transplantation. Most graft-infiltrating cells 
are detected as CD3  T lymphocytes. Hmox-1 expression is mainly local-
ized at epithelial cells in Hmox-1 /  allografts and is overexpressed after 
CoPP treatment. Some cells expressing iNOS are recognized as CD3  T lym-
phocytes. The donor Hmox-1 genotype and treatment regimen are indicated. 
The conditions shown are described in the legend to Fig. 1. Bar, 50  m. 
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ferent for Hmox-1, in that Hmox expression in the graft,
rather than in the recipient, dominates the course of rejec-
tion. Exacerbation of the airway occlusive lesions was ob-
served when the grafts themselves lacked the 
 
Hmox-1
 
 gene;
however, lesions were not exacerbated when the graft tissue
expressed Hmox-1, but circulating recipient cells were
Hmox-1 null (Fig. 2 B). These differences could not be ac-
counted for by differences in the background strain because
graft luminal narrowing for Hmox-1
 
 
 
/
 
 
 
 trachea transplanted
into Hmox-1
 
 
 
/
 
 
 
 recipients was similar when the reverse
background strain combination (i.e., B10.A donors trans-
planted into 129Sv 
 
 
 
 BALB/c recipients) was used (Fig. 2
B). Thus the “protection” conferred by Hmox-1 cannot be
ascribed to the reversal of donor and recipient strains, which
in other model systems can affect the course of rejection de-
spite identical allogeneic disparity (10). These data suggest
that Hmox-1 expressed by graft epithelium, rather than by
graft-infiltrating leukocytes, exerts the dominant influence
on airway rejection.
To further delve into the pathway by which CO reduces
graft luminal occlusion, a selective inhibitor of GC,
1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) was
given to Hmox-1
 
 
 
/
 
 
 
 allograft recipients during the period of
CO inhalation. These data show that inhibition of GC dur-
ing CO exposure did not interfere with the suppressive ef-
fect of exogenous CO inhalation on graft occlusion (35 
 
 
 
2% for CO 
 
 
 
 ODQ treatment in Hmox-1
 
 
 
/
 
 
 
 allografts,
31 
 
 
 
 3% for CO exposure alone; P 
 
  
 
NS), indicating that
CO elicits its beneficial effects through a cyclic cGMP-inde-
pendent pathway.
 
Immunoreactivity for Hmox-1, CD3, and iNOS 
in adjacent sections
 
The prominent mononuclear cell infiltrate that was observed
was comprised primarily of T cells, as determined by immu-
nohistochemical analysis for the pan–T cell marker CD3 (Fig.
3, a–f ). Quantitation of CD3 positive cells in histological sec-
tions reveals an approximate doubling of the number of CD3
positive cells in Hmox-1
 
 
 
/
 
 
 
 allografts compared with Hmox-
1
 
 
 
/
 
 
 
 allografts. Immunoreactivity for Hmox-1 in epithelial
cells was detected strongly in CoPP-treated Hmox-1
 
 
 
/
 
 
 
 al-
lografts (Fig. 3 i) and moderately in Hmox-1
 
 
 
/
 
 
 
 allografts
(Fig. 3 h), but was hardly detectable in Hmox-1
 
 
 
/
 
 
 
 allografts
(Fig. 3 k). Some graft-infiltrating cells (lymphocytic predomi-
nance) express Hmox-1 in each allograft (Fig. 3, h–l). These
data indicate that epithelial cells in allografts represent a major
source of Hmox-1 expression. iNOS expression was localized
in both epithelial cells and infiltrating cells (Fig. 3, m–r),
which were partly recognized as CD3
 
 
 
 lymphocytes detected
in adjacent serial sections. Immunoreactivity for iNOS was
strongly expressed in graft-infiltrating lymphocytes in Hmox-
1
 
 
 
/  allografts (Fig. 3 q). CO exposure for 2 wk prevented
up-regulation of iNOS in both Hmox-1 /  (Fig. 3 p) and
Hmox-1 /  allografts (Fig. 3 r).
Figure 4. Northern and Western blots showing levels of Hmox-1 
(HO-1) and Hmox-2 (HO-2) in grafts. All recipients were Hmox-1 /  
(donor genotypes are indicated in the figure). (A and C) Effect of CoPP, 
ZnPP, or CO inhalation on Hmox-1 mRNA (n   4 ) and protein (n   5 ) 
levels. (B and D) The same effects for Hmox-2 mRNA and protein. The rep-
resentative blots and treatment regimen are indicated under the bars, 
which display the densitometric mean   SEM relative to  -actin (normal-
ized to isograft values). The y axis indicates the fold increase versus 
isograft. ISO, isografts; NT, nontransplanted recipients; *, P   0.05 versus 
Hmox-1 / ; #, P   0.05 versus Hmox-1 /  allografts.JEM VOL. 202, July 18, 2005 287
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Induced levels of mRNA and protein for Hmox-1 
and Hmox-2 in airway grafts
To quantify the levels of both mRNA and protein for
Hmox-1 and Hmox-2 induction in airway grafts, Northern
and Western blots were performed on graft tissue extracts.
Normalized Hmox-1 levels for both mRNA (Fig. 4 A) and
protein (Fig. 4 C) were significantly increased in Hmox-1 / 
allografts compared with isografts (22-fold and 25-fold in-
creases, respectively; P   0.05 for both comparisons). Levels
of both Hmox-1 mRNA and protein in Hmox-1 /  al-
lografts were up-regulated by CoPP treatment (both twofold
increases; P   0.05). Paradoxically, treatment with ZnPP also
caused an increase in levels of Hmox-1 mRNA and protein
in Hmox-1 /  allografts (1.6-fold and 2-fold increases, re-
spectively; P   0.05 for protein levels; reference 11). No sig-
nificant increase was seen after exogenous CO exposure. In
Hmox-1 /  allografts, the expression of both Hmox-1
mRNA and protein in Hmox-1 /  allografts was also in-
creased compared with that seen in isografts (16-fold and 17-
fold increases, respectively; P    0.05 for protein levels).
Colocalization experiments confirm that this is primarily sec-
ondary to Hmox-1 expression in the infiltrating cells, rather
than allograft material (Fig. 5, A and B). Graft expression of
Hmox-2 mRNA (Fig. 4 B) and protein (Fig. 4 D) was de-
tected at the same low levels in all groups. There was no ef-
fect of CO exposure on expression of Hmox-1 and Hmox-2
in fresh tracheal tissue taken from nontransplanted mice.
Hmox activity and blood levels of COHb
Hmox enzymatic activity was measured based on the stoi-
chiometric production of biliverdin and CO from heme
substrate. After enzymatic reduction of biliverdin to biliru-
bin, tissue concentrations of bilirubin measured in Hmox-
1 /  allografts were found to be 2.7-fold higher than those
in isografts (Fig. 6 A). Compared with Hmox-1 /  al-
lografts, the levels of Hmox activity were substantially in-
creased by CoPP treatment (3.5-fold increase; P   0.05),
but reduced (1.7-fold decrease) by Hmox-1 gene deficiency
(Hmox-1 /  allografts). Exogenous CO inhalation did not
affect the enzymatic activity. Blood levels of COHb mea-
sured at the time of death were significantly (P   0.05) in-
creased only when CoPP was given to mice (Fig. 6 B).
Effect of exogenous CO/NO exposure on cGMP levels 
in tracheal tissue
cGMP levels in nontransplanted native trachea were signifi-
cantly (P   0.05) elevated after either 1 d (10-fold increase)
or 2 wk of 20 ppm NO exposure (an 8-fold increase). CO
exposure (250 ppm) almost doubled cGMP levels at 1 d
(P   NS), although cGMP levels returned to baseline levels
after 2 wk (Fig. 6 C).
Effect of Hmox-1 induction and exogenous CO exposure 
on iNOS expression
Because iNOS expression has been causally implicated in the
outcome of graft rejection, mRNA (Fig. 7 A) and protein
(Fig. 7 B) levels in grafts were quantified. Both iNOS
mRNA and protein levels were significantly increased in
Hmox-1 /  allografts compared with isografts (14-fold and
19-fold increases, respectively; P   0.05 for each compari-
son). Compared with Hmox-1 /  allografts, iNOS up-regu-
lation was detected in both Hmox-1 /  allografts (1.7-fold
increase for message and 2-fold increase for protein levels;
P   0.05 for protein levels) and ZnPP-treated Hmox-1 / 
allografts (1.3-fold increase for protein levels). CoPP treat-
ment in Hmox-1 /  allografts, however, suppressed iNOS
induction (1.9-fold decrease for mRNA, P   NS; 2-fold de-
crease for protein levels, P   0.05) versus Hmox-1 /  al-
lografts. iNOS levels in Hmox-1 /  allografts were also sup-
pressed by exogenous CO exposure (2.3-fold decrease for
Figure 5. Confocal microscopic assessment of specific leukocyte 
populations expressing Hmox-1. Colocalization of Hmox-1 and CD3 (A) 
and Hmox-1 and F4/80 (marker of macrophages; panel B) in Hmox-1 /  
allografts. CD3  T cells and F4/80  macrophages were labeled with FITC 
and detected as a green emission. Hmox-1  cells were labeled with PE and 
detected as a red emission. Sites of colocalization are indicated as a yellow 
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mRNA and 1.8-fold decrease for protein levels; P   0.05 vs.
Hmox-1 /  allografts for both comparisons). There was no
effect of CO exposure on iNOS expression in fresh tracheal
tissue taken from nontransplanted mice.
NO production assay
The levels of stable oxidant byproducts of NO (NO2
  and
NO3
 ) in airway grafts were determined as the total concen-
tration of nitrite after conversion of all the sample NO3
 
into NO2
  using nitrate reductase (Fig. 7 C). Compared
with isografts, increased levels of nitrite (5.3-fold; P   0.05)
were detected in Hmox-1 /  allografts. Nitrite levels were
increased further after ZnPP treatment (twofold increase;
P   0.05 vs. Hmox-1 /  allografts) and even more signifi-
cantly increased in Hmox-1 /  allografts (3.9-fold increase;
P   0.05 vs. Hmox-1 /  allografts). On the other hand, ni-
trite levels were reduced by either CoPP treatment (2.5-fold
decrease) or exogenous CO exposure (2.8-fold decrease)
compared with Hmox-1 /  allografts. Exposure of Hmox-
1 /  allografts to inhaled CO also decreased NO production
(2.2-fold decrease; P   0.05 vs. Hmox-1 /  allografts).
Effect of Hmox-1 induction and exogenous CO inhalation 
on iNOS-specific NF- B binding activity
The striking down-regulation of iNOS expression by CO,
which may account for some of the biological potency of
CO as an inhibitor of airway allograft rejection, led us to in-
vestigate whether CO affects transcriptional regulation of the
iNOS gene in transplanted airway tissue. There are two
Figure 6. Hmox enzymatic activity in airway grafts. (A) Hmox 
enzyme activity was determined as the level of bilirubin generated in graft 
tissue (n   5). *, P   0.05 versus Hmox-1 / . Data are mean   SEM. 
(B) Arterial blood levels of COHb were measured at the time of recipient 
sacrifice (n   5). The donor Hmox-1 genotype and treatment regimen are 
indicated under each bar. ISO, isografts; NT, nontransplanted recipients; 
*, P   0.05 versus CoPP-treated Hmox-1 /  allografts. Data are mean 
  SEM. (C) Acute (1 d) and prolonged (2 wk) effects of CO/NO inhalation 
on cGMP levels in nontransplanted tracheal tissue (n   3).
Figure 7. Effect of graft Hmox-1 genotype, treatment with CoPP, 
ZnPP, and CO on graft iNOS induction. (A and B) Analysis of iNOS 
mRNA and protein expression by Northern (n   4) and Western (n   5) 
blotting. Representative blots, corresponding donor Hmox-1 genotype, 
and treatment regimen are indicated under each bar.  -Actin was used 
to control for lane loading. The y axis indicates the fold increase versus 
isograft. (C) Total NO production (measured as nitrite in reduced samples) 
in airway grafts measured at 3 wk after transplantation (n   5). ISO, 
isografts; NT, nontransplanted recipients. *, P   0.05 versus Hmox-1 / ; 
#, P   0.05 versus Hmox-1 /  allografts. Data are mean   SEM.JEM VOL. 202, July 18, 2005 289
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known NF- B binding sites in the iNOS promoter region,
one upstream (NF- Bu) and one downstream (NF- Bd).
Electrophoretic mobility shift assay (EMSA) was performed
to investigate the binding activity for each (Fig. 8 A, NF-
 Bu, and B, NF- Bd). Transplantation resulted in insubstan-
tial changes in NF- Bu DNA binding activity in tissue taken
from all conditions studied, suggesting minor or no involve-
ment of this promoter site in iNOS gene regulation in the
setting of airway transplantation. In contrast, NF- Bd was
activated in the setting of allograft transplantation. In al-
lografts in which Hmox activity was pharmacologically (by
ZnPP) or genetically reduced (Hmox-1 / ), there was clear
up-regulation of formation of binding complexes in the
downstream NF- B site in the iNOS promoter. On the
other hand, allografts in which Hmox-1 was pharmacologi-
cally up-regulated (with CoPP) or which had been treated
with 250 ppm of chronic exogenous CO for 2 wk showed
substantially less NF- Bd activation. No binding complexes
(for either NF- Bu or NF- Bd) were detected in untreated
isografts, nor in tracheas from nontransplanted control mice
exposed to CO. Specificity of these results was demon-
strated by supershift experiments. The binding complex was
blocked and supershifted by antibody to p65, an NF- B/Rel
family member, using nuclear extracts from Hmox-1 /  al-
lografts (Fig. 8 C). A similar supershift was seen when a
combination of anti-p50 and -p65 was used. The binding
specificity of the NF- Bd complex was further ascertained
by competition with unlabeled oligonucleotides. Further-
more, three-color fluorescent immunostaining demonstrated
that immunoreactivity for p65 (red) was mainly detected in
nuclei (blue) of CD3  T lymphocytes (green) infiltrating
Hmox-1 /  allografts (Fig. 8 D). Collectively, these findings
suggest that activation of Hmox-1 in allografts reduces the
formation of a sequence-specific NF- Bd complex com-
prised of mainly p65 homodimers (12) in allograft tissue. Ex-
posure of recipient mice to CO can completely substitute for
this inhibitory effect of activated Hmox-1 in allografts.
IL-1  expression and localization
IL-1  levels in grafts were determined by Western blot anal-
ysis (Fig. 9 A). Compared with isografts, protein levels of IL-
1  in Hmox-1 /  allografts were significantly up-regulated
(15-fold increase; P   0.05). Although neither administra-
tion of the Hmox inducer CoPP nor exogenous CO expo-
sure affected IL-1  expression in Hmox-1 /  allografts, IL-1 
was strongly induced in the setting of Hmox-1 gene defi-
ciency (2.5-fold increase; P    0.05 vs. Hmox-1 /  al-
lografts). Chronic CO treatment, however, strongly sup-
pressed IL-1  induction in Hmox-1 /  allografts (2.8-fold
decrease; P   0.05 vs. Hmox-1 /  allografts). Localization
of IL-1  was determined using a digital deconvolution sys-
tem. IL-1  expression (red) was mainly localized in epithe-
Figure 8. NF- B binding activity in both upstream (NF- Bu) and 
downstream (NF- Bd) regions of the iNOS promoter by EMSA. 
(A and B) Binding activity was detected on NF- Bd but not NF- Bu. (C) Super-
shift assay using nuclear extracts prepared from Hmox-1 /  allografts. Ex-
tracts were incubated with or without the indicated antibodies or a 50-fold 
molar excess of unlabeled oligonucleotide probe as a competitor. The donor 
Hmox-1 genotype and treatment regimen are indicated under each lane. 
ISO, isografts; NT, nontransplanted recipients. (D) Intracellular expression of 
p65 identified as a red emission after the application of an excitation wave-
length of 594 nm. CD3  T cells were labeled with FITC and detected as a 
green emission; nuclei (counterstained with DAPI) are identified by the blue 
emission spectra. Sites of colocalization are indicated by arrows. Bar, 5  m.REGULATION OF AIRWAY REJECTION BY HMOX-1 AND INOS | Minamoto et al. 290
lial lining cells in Hmox-1 /  allografts, but also detected in
CD3  T-lymphocytes (Fig. 9 B, green). Histological data
using this technique show that exogenous CO exposure re-
duced the expression of IL-1  in epithelial cells (Fig. 9 C),
in excellent concordance with the Western blot data.
DISCUSSION
NO and CO, both diatomic gases that bind to heme and ac-
tivate GC, have entirely opposite effects in the setting of air-
way transplantation. When acutely inhaled after isogeneic rat
lung transplantation, inhaled NO was without effect on vas-
cular resistance, gas exchange, leukocyte infiltration, or re-
cipient survival (13). When exogenous NO is inhaled for 2
wk at a dose of 20 ppm, there is essentially no effect on re-
jection in a rat model of lung allograft transplantation (14).
In the present studies, 20 ppm of inhaled NO given for 2 wk
in a murine air-flow permissive model of airway transplanta-
tion not only fails to reduce allograft airway occlusion but
actually increases it slightly. Endogenous expression of iNOS
is frankly pathological in this same murine model of airway
transplantation (2). iNOS expression increases local expres-
sion of MIP-1  and RANTES, exacerbates development of
a CD3 CD8  T cell lymphocytic bronchitis, and ultimately
contributes to airway luminal obliteration (2). These data are
in sharp contrast to the role of endogenous Hmox expres-
sion and local CO generation, or the effect of exogenous
CO administration. In the current experiments, both endog-
enous and exogenous CO were shown to have a remarkable
salutary effect on the transplanted airway, reducing expres-
sion of inflammatory cytokines, leukocyte traffic, and even-
tual luminal obliteration.
Several lines of evidence point to the fact that the antire-
jection effects of CO are sGC independent. Even though in-
haled doses of CO (250 ppm) and NO (20 ppm) were cho-
sen for study based on theoretically similar levels of sGC
stimulation (CO induces a 4.4-fold activation of purified
sGC vs. a 130-fold activation of the enzyme by NO), only
inhaled CO but not inhaled NO had a protective effect.
Perhaps the strongest evidence comes from experiments in
which pharmacological inhibition of GC with ODQ did not
abrogate the beneficial effects of CO. Other authors (15–17)
have shown that certain effects of CO, such as its antiapop-
totic effects on endothelial cells, are cGMP independent. In
that work, activation of p38 mitogen-activated protein ki-
nase was shown to underlie the antiapoptotic effects of CO.
It is possible that similar mechanisms might apply in our
model of OB. To investigate the potential link between CO
and NO, the effect of CO on iNOS induction was explored.
Inhalation of CO results in marked suppression of NF-
 B activation, an upstream transcriptional event that triggers
several proinflammatory processes. NF- B is an important
acute phase immune regulator, as well as a regulator for de-
velopment of T lineage cells (18) and T cell–dependent im-
mune responses (19). NF- B also has an important facilitory
role in allograft rejection, including expression of chemokine
and cytokine production (20). NF- B is also a potent regu-
lator of iNOS transcription (21). Of the two putative NF-
 B regulatory binding sites in the iNOS promoter region,
NF- Bd appears to be more importantly involved in induc-
tion of the iNOS gene than NF- Bu in LPS-stimulated
macrophages (21) or in tracheal allografts (Fig. 8 B). Our
data strongly support the hypothesis that Hmox-1–derived
CO is responsible for suppressing NF- B activation, thereby
reducing iNOS gene transcription. Superinduction of
Hmox-1 with CoPP treatment was associated with a pro-
found reduction in NF- B/DNA binding in wild-type al-
lograft nuclear extracts. The suppressive effect of Hmox-1
Figure 9. Effect of graft Hmox-1 genotype, treatment with CoPP, 
ZnPP, and CO inhalation on graft IL-1  induction. (A) Analysis of IL-1  
protein expression by Western blotting (n   5). Representative blots, corre-
sponding donor Hmox-1 genotype, and treatment regimen are indicated 
under each bar.  -Actin was used to control for lane loading. ISO, isografts; 
NT, nontransplanted recipients; *, P   0.05 versus Hmox-1 /  allografts; 
#, P   0.05 versus Hmox-1 /  allografts. (B) Intracellular expression of 
IL-1  (identified as the red emission) is mainly detected in epithelial cells 
(arrowhead) of a representative section taken from Hmox-1 /  allografts. 
CD3  T cells labeled with FITC (detected as the green emission) also have 
some expression of IL-1  (arrows). (C) Exogenous CO treatment reduced 
IL-1  expression in epithelial cells of Hmox-1 /  allografts. Bar, 5  m.JEM VOL. 202, July 18, 2005 291
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on iNOS gene transcription is further demonstrated by the
increased nuclear binding activity of the downstream site of
NF- B in Hmox-1 /  allografts and by the remarkable in-
duction of iNOS mRNA and protein detected in this same
group. Furthermore, our data suggest that CO is directly re-
sponsible for the Hmox-1–mediated suppression of iNOS,
because exogenous CO inhalation decreased expression of a
DNA binding protein corresponding to NF- Bd on EMSA
and also decreased iNOS mRNA and protein expression.
This does not preclude obligatory or secondary involvement
of other signaling cascades, such as mitogen-activated pro-
tein kinase cascades, but this represents an opportunity for
future investigation. Our data support the hypothesis that
CO exerts its beneficial effects on the transplanted allogeneic
airway by suppressing NF- B activation, reducing iNOS in-
duction, and, thus, attenuating the alloimmune response (2).
iNOS expression has been described as a deteriorative
mediator in chronic rejection after lung transplantation (22).
This damaging effect of iNOS may involve a peroxynitrite
intermediary, as nitrotyrosine staining provides evidence of
the reaction of NO with superoxide anion, and there is
abundant data to support the toxicity of peroxynitrite (23).
The increased presence of iNOS in allografts, especially leu-
kocyte-derived iNOS rather than epithelium derived iNOS,
appears to be most responsible for OB (2). We showed that
expression of iNOS and generation of NO product in
Hmox-1 /  allografts were enhanced by graft Hmox-1 defi-
ciency, leading to promotion of the rejection process,
whereas either activation of Hmox-1 in Hmox-1 /  al-
lografts or exogenous CO inhalation in both Hmox-1 / 
and Hmox-1 /  allografts down-regulated iNOS expres-
sion, resulting in improvement of graft luminal narrowing. A
further suppressive effect for luminal occlusion was not seen
by combined treatment of CO exposure and pharmacologi-
cal iNOS inhibition with L-NIL during the early postopera-
tive period, suggesting that exogenous CO may abrogate the
involvement of iNOS in the process of allograft rejection.
The diminution of nitrite likely reflects a global reduction in
iNOS activity, which might be secondary to an interaction
of CO with the heme in iNOS. An in vitro study (24) also
supports our data, in that it reports that CO, but not biliru-
bin treatment, reduced LPS-induced iNOS expression and
NO production.
The tremendous disparity between the data with inhaled
NO (harmful with chronic inhalation) and inhaled CO
(beneficial with chronic inhalation) do not imply that low
doses of inhaled NO are useless in the acute lung transplant
setting. When given to the pulmonary donor before lung
harvest, inhaled NO blunts the decline in tissue cGMP levels
and improves vascular function after lung transplantation in
an isogeneic rat lung transplant model (13). When adminis-
tered to patients after lung transplantation, inhalation of low
levels ( 80 ppm) of NO acts as a pulmonary vasodilator and
platelet inhibitor that ameliorates early graft dysfunction (9).
The failure of the sGC blockade to detract from the benefi-
cial effect of long-term inhaled CO, as well as other evi-
dence cited above, suggests that chronic CO does not work
through a cGMP-based mechanism. Although there are sev-
eral potential cGMP-independent mechanisms by which
CO might exert its antirejection effects in airways, such as by
modulating the activity of p38 (7) or ERK 1/2 (25) mito-
gen-activated protein kinase pathways, our data point to the
strong possibility of an inhibitory effect on NF- B activa-
tion, iNOS up-regulation, and cytokine induction through
the cGMP-independent pathway.
Although alloimmune effector cells access the graft ablu-
minally, it is clear that gases flowing over the airway luminal
surface can fundamentally alter the biological properties of
the graft and its infiltrating cells. We show that induction of
Hmox-1 expression with CoPP increases endogenous CO
generation, as evidenced by increased levels of COHb in ar-
terial blood from CoPP-treated recipients. The contribution
of Hmox-1 overexpression in Hmox-1 /  allografts, which
was strongly protective against airway obliteration, could be
completely replicated by exogenous CO inhalation in
Hmox-1 /  allografts. Lack of the Hmox-1 gene, or Hmox
blockade with ZnPP, exacerbated allograft rejection and re-
sulted in an increase of luminal narrowing, which was also
suppressed by exposure of CO. The pharmacological inhibi-
tion of Hmox activity using ZnPP did not show the same
exacerbation of luminal obliteration as seen in as Hmox-1 / 
allografts. This might be because of the lack of specificity
of ZnPP (11). It has also been reported that some metal-
loporphyrins, including ZnPP, can induce transcription of
Hmox-1 (11). These data implicate CO generation as the
dominant protective effector mechanism elicited by Hmox-1
expression in airway allograft rejection. Even though cyto-
protective effects elicited by another catalytic byproduct of
heme degradation (biliverdin) or subsequent bilirubin and
ferritin formation might contribute to protection by antioxi-
dant or other properties, the current findings suggest that the
preeminent role for CO formation by Hmox-1 is in the mit-
igation of acute-on-chronic airway rejection.
If endogenous Hmox-1 expression increases secondary
to the transplantation procedure, and if Hmox-1 is protec-
tive, one may wonder why, in Hmox-1 /  allografts, rejec-
tion develops at all. Our data here, as well as elsewhere in
unrelated model systems, show that endogenous expression
of Hmox-1 is protective only to a point; overexpression
studies (using a chemical inducer [26, 27] or a transgene [27,
28]) reveal consistent ability to augment this endogenous
protective mechanism. In our experiments, the protective
effects of Hmox-1 against allograft luminal occlusion are
maximal when the gene is overexpressed. This protection is
not limited only to increased patency of the airway lumen,
but also to reduced local proinflammatory cytokine expres-
sion and reduced recruitment of cytoeffector leukocyte pop-
ulations. These other features may in fact contribute to the
ultimate beneficial effects that are observed with Hmox-1
overexpression or CO inhalation.
Our previous study (2) indicated that iNOS expression
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with the occurrence and severity of graft rejection. How-
ever, local epithelial expression of iNOS did not play a role
in this process, as iNOS /  airway allografts placed in
iNOS /  recipients developed the same amount of disease as
iNOS /  grafts placed in iNOS /  recipients. This is in
striking contrast to the Hmox-1 data presented here, in
which local expression of Hmox-1 is shown to be of prime
importance in suppressing airway rejection. The relative
contribution of airway epithelial Hmox-1 expression versus
Hmox-1 expression in recipient graft-infiltrating leukocytes
was ascertained by transplanting Hmox-1 /  airway grafts
into allogeneic Hmox-1 /  recipients or by transplanting
the reverse combination (Hmox-1 /  donor tissue into
Hmox-1 /  recipients). Results demonstrated significantly
increased (P   0.05) allograft luminal occlusion when
Hmox-1 was absent in donor but not recipient tissue, impli-
cating a critical contribution of epithelium-derived Hmox-1,
rather than infiltrating leukocyte-derived Hmox-1, in sup-
pressing development of airway rejection. These results also
suggest that inhalation of exogenous CO, which is likely to
act most immediately on epithelial cells into which it first
comes into contact, may be particularly efficacious in the
setting of lung transplantation.
Collectively, the current results suggest a new paradigm
for an endogenous protective mechanism against airway re-
jection (epithelium-derived Hmox-1 and CO), which can be
bolstered by chronic inhalation of exogenous CO gas. It is
intriguing that another diatomic gas, NO, which even more
potently stimulates GC, has a facilitating effect on airway re-
jection, either when expressed endogenously (via iNOS) or
when inhaled. The immunosuppressant effects of CO in this
model of airway rejection are not only GC independent, but
are associated with reduced NF- B binding in the iNOS
promoter and reduced up-regulation of iNOS. These data,
therefore, highlight the negative reciprocal interactions be-
tween two quintessential biological diatomic gases (CO and
NO) and the enzymes that produce them.
MATERIALS AND METHODS
Mice. B10.A (H2a) mice were purchased from the Jackson Laboratories.
For certain experiments, male Hmox-1 /  mice (129Sv   BALB/c back-
ground) were used (29) with Hmox-1 /  progeny serving as littermate
controls. The genotype was confirmed by genomic PCR (30). All mice
were between 7 and 15 wk old (25–30 g). Isogeneic tracheal transplants
were performed using B10.A mice as both recipients and donors. Alloge-
neic (129Sv   BALB/c) tracheal grafts from wild-type (Hmox-1 / ) or
Hmox-1 /  donor mice were transplanted into wild-type (B10.A) recipient
mice. To specifically determine the role of epithelial- versus leukocyte-
derived Hmox-1, reverse donor/recipient transplantation experiments were
performed using wild-type donor (B10.A) airway allografts transplanted into
Hmox-1 /  or Hmox-1 /  recipients. All experiments were performed ac-
cording to protocols approved by the Association for Assessment and Ac-
creditation of Laboratory Animal Care guidelines.
Tracheal transplantation, immunosuppression, sample acquisition,
and CO measurements. Experiments were performed in a recently de-
scribed double-lumen airway transplant model for studying chronic airway
rejection (2). In brief, donor mice were exsanguinated after anesthesia, and
whole tracheas were harvested by transecting below the cricoid cartilage
distal to the carinal bifurcation under sterile conditions. Recipient mice
were similarly anesthetized, and whole tracheas were exposed. Distal (the
sixth intercartilaginous space) and proximal (immediately subjacent to the
cricoid cartilage area) orifices positioned on the recipient trachea were anas-
tomosed with both ends of the tracheal graft.
All recipient animals received postoperative intramuscular immunosup-
pression (25 mg/kg/d cyclosporine; Bedford Laboratories) for 2 wk, to
model acute-on-chronic airway rejection, and antibiotics (20 mg/kg/d ce-
fazolin sodium; Apothecon) for 3 d. All recipient animals survived and were
killed at 3 wk after transplantation. The percent COHb content of 100  l
of arterial blood was determined using a CO-oximeter (Nova; Waltham) at
the time of death. Tracheal grafts were harvested and snap frozen or embed-
ded en bloc with the native tracheas in Tissue Freezing Medium (Triangle
Biomedical Sciences) in a cryomold in liquid nitrogen and stored at  80 C
until the time of analysis.
Pharmacological regulation of Hmox-1 induction. To induce Hmox-1
expression during the rejection process, wild-type donor or recipient mice were
given 5 mg/kg CoPP (Frontier Scientific) i.p. at days 5 and 1 before transplan-
tation to the donor and days 0 and 5 after transplantation to the recipient (26).
The effect of CoPP on endogenous CO production was confirmed by mea-
surements of graft Hmox-1 expression and levels of COHb in arterial blood at
the time of death, as described in the previous section. Hmox activity was in-
hibited using 20 mg/kg ZnPP (Frontier Scientific), a competitive inhibitor, ad-
ministered i.p. (27) at the same times as described for CoPP.
Exogenous CO/NO exposure. Mice that were exposed to CO or NO
(or controlled room air exposure) were treated as follows. Cages were
placed in a lucite exposure chamber (30) immediately after tracheal trans-
plantation and exposed to either 250 ppm CO (balanced with air) or 20
ppm NO (blended with air just before exposure; TechAir). These concen-
trations of CO (7, 24, 26, 31) or NO (32) were based on previous reports of
their use in different model systems. CO levels in the chamber were main-
tained at 250 ppm monitored with a CO detector (PhD Ultra; Biosystems).
NO level was maintained at 20 ppm, keeping the NO2 level  5 ppm by
flowing freshly blended gas into the chamber and monitoring with a detec-
tor (Q-RAE; Geotech). Exposure was initiated immediately after comple-
tion of the surgical procedure. Recipient mice were removed from the
chamber for only the time required for the daily injection (immunosuppres-
sor or pharmacological inhibitor). After 2 wk, cages were placed in room air
for the remaining 1 wk until death. Nontransplanted mice were killed im-
mediately after 2 wk of CO or NO exposure, at which time blood samples
were collected from the left ventricle for measurement of COHb levels. In
nontransplanted mice, native tracheal segments were also harvested in order
to determine the possible effects of these gases on the tissue levels of cGMP
(1 d or 2 wk of CO or NO exposure) or expression of Hmox-1, Hmox-2,
iNOS, and IL-1  (2 wk of CO or NO exposure). For experiments to eval-
uate the effect of CO administration to the donor, donor mice were ex-
posed to CO over 24 h before graft harvesting, and the grafts were trans-
planted into recipient mice without further CO exposure.
Pharmacological inhibition for cGMP and iNOS induction. In cer-
tain experiments coincident with the placement of Hmox-1 /  allograft re-
cipient animals in the CO chamber, mice were given a daily dose of 5 mg/
kg ODQ intramuscularly (33) for 2 wk after transplantation. In experiments
designed to study the combined effects of CO exposure and iNOS suppres-
sion, both Hmox-1 /  and Hmox-1 /  allograft-recipient mice were
placed in the CO chamber for 2 wk, during which time they were given 5
mg/kg of the selective iNOS inhibitor L-NIL (Cayman Chemical) i.p.
daily, a treatment that was continued into the third week after transplanta-
tion, as previously reported (2).
Histopathological evaluation. 5- m-thick frozen sections were cut and
placed on glass slides (Fisher Scientific), after which sections were air dried
and fixed for 15 min in acetone at 4 C. Histochemical staining was per-JEM VOL. 202, July 18, 2005 293
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formed for elastin (Accustain; Sigma-Aldrich) in order to determine graft lu-
minal occlusion. Immunostaining was also performed using serial adjacent
sections from each group, with primary antibodies directed against a pan–T
cell marker (hamster anti–mouse CD3; BD Biosciences), Hmox-1, Hmox-2
(rat anti–mouse Hmox-1 and rat anti–mouse Hmox-2; StressGen Biotech-
nologies), or iNOS (rabbit anti–mouse iNOS; Transduction Laboratories).
Morphometric measurements of cross-sectional areas were performed
by blindly tracing both epithelial and subepithelial areas using a computer-
assisted image analysis system (AxoCamHR; Carl Zeiss MicroImaging, Inc.).
Localization of sites of intracellular NF- B expression was determined
with a digital deconvolution system (Isee Imaging Systems) using a fluores-
cence microscope (Axiovert S100; Carl Zeiss MicroImaging, Inc.). A series
of images was generated from multiparameter (three-color) immunofluores-
cent staining techniques. After blocking nonspecific binding and FcRs with
normal goat serum and the FcR blocker anti-2.4G2 (BD Biosciences),
CD3  T cells were detected by FITC-conjugated antibodies (anti–mouse
CD3; BD Biosciences). Sections were then fixed and permeabilized using a
Cytofix/CytopermTM kit (BD Biosciences). Each section was then incu-
bated with rabbit anti–mouse p65 (Santa Cruz Biotechnology, Inc.), rabbit
anti–mouse IL-1  (Cell Sciences), or rabbit IgG (as a negative control) at
4 C for 30 min in the dark. Intracellular NF- B or cytokine (IL-1 ) were
identified by incubating the sections with a fluorescent secondary antibody
(AlexaFluor 594 goat anti–rabbit IgG; Molecular Probes) followed by a nu-
clear counterstain (DAPI).
Northern blotting. The cDNA probe for the detection of iNOS mRNA
was prepared as described previously (2). RT-PCR was performed to make
Hmox-1 and Hmox-2 cDNA probes. Primers for mouse Hmox-1 and
Hmox-2 were directed at regions 125/1323 (available from GenBank/
EMBL/DDBJ under accession no. NM 010442) and 139/1137 (available
from GenBank/EMBL/DDBJ under accession no. XM 147238) of each
gene, respectively, producing a 1,198- and a 998-bp product for each respec-
tive reaction. The forward and reverse primers sequences for Hmox-1 were
5 -GTGATGGAGCGTCCACAGCCCGACA-3  and 5 -AAAGTGGC-
CATGGCACTGGGGGACA-3 . The sequences for Hmox-2 were 5 -
GGGCAGCACAAACTACTCAGCCACA-3  and 5 -GGGATAGAA-
CAGGTCACTTGGGGTA-3 . The RT-PCR product mixture was ex-
tracted and inserted into pCRII Vector using the TA cloning method (Invi-
trogen). The cDNA expression plasmid was confirmed by enzyme cut and
was also sequenced (ABI Prism 310; PE Biosystems). Total RNA was iso-
lated from each tracheal graft after tissue homogenization, and 15  g of each
was electrophoresed and transferred to nitrocellulose membranes. Specific
mRNAs were identified by hybridization to the indicated probes labeled
with  -[32P]dCTP. Normalized absorption values were obtained by densitom-
etry scanning of labeled bands (National Institutes Health Image 1.62; Na-
tional Institutes of Health), including  -actin bands. Expression of each band
was normalized with its corresponding  -actin band, and this ratio was then
normalized with that of the isograft sample for each experiment.
Western blotting. SDS-PAGE gels were loaded with samples of tissue
protein (30  g/lane), subjected to electrophoresis, transferred electro-
phoretically to nitrocellulose membranes, and reacted with the following
primary antibodies: anti–Hmox-1, Hmox-2, and iNOS (the same primary
antibodies as in immunohistochemistry), and rabbit anti–mouse IL-1  (Cell
Sciences). Secondary detection of primary antibody localization was accom-
plished using horseradish peroxidase–conjugated antibodies directed against
the appropriate species (Sigma-Aldrich). Bands were revealed using the
chemiluminsecent method of detection on X-ray film (GE Healthcare). Ex-
pression of each band was normalized to its corresponding  -actin band
(mouse anti– -actin; Sigma-Aldrich), and this ratio was then normalized
with that of the isograft sample for each experiment.
Measurement of Hmox activity. Hmox enzymatic activity was deter-
mined by measuring bilirubin generated in transplanted airway grafts (34).
Tissue was homogenized in protein extract solution containing 0.6% NP-40
(Roche), 150 mM NaCl, 10 mM Hepes, pH 7.9, 1 mM EDTA, and 0.5 mM
PMSF (Sigma-Aldrich) on ice, and centrifuged at 13,000 g for 10 min at 4 C.
After determination of protein levels, measured using the Bradford method
(Bio-Rad Laboratories), supernatants were incubated for 1 h at 37 C in the
dark with the 200- l reaction mixture containing mouse liver cytosol (1 mg
of protein), 50  M hemin, 1 mM NADPH, 2 mM glucose 6-phosphate, and
0.2 U glucose-6-phosphate dehydrogenase (Sigma-Aldrich) in 0.1 M potas-
sium phosphate buffer, pH 7.4. Bilirubin produced in this reaction was mea-
sured spectrophotometrically ( OD at 464–530 nm; extinction coefficient,
40 mM/liter/cm for bilirubin). Hmox activity is expressed as micromoles of
bilirubin formed per milligram of protein per hour ( mol/mg protein/hr).
The background activity of the reaction mixture with liver cytosolic extract
alone (without tracheal tissue homogenate) was subtracted from each sample
reaction to determine the specific activity of the added sample.
Measurement of NO production. To determine concentrations of the
final products of NO in airway grafts, the total concentration of nitrite in
the protein extracts of grafts was measured using an NO detection kit
(StressGen Biotechnologies). Values were normalized per milligram of cor-
responding tissue protein ( M/mg protein).
Tracheal cGMP assay. To demonstrate the effect of exogenous CO or
NO exposure on cGMP levels in tracheal tissue, enzyme immunoassays
were performed using commercial kits (cGMP EIA Kit; Cayman Chemi-
cal). Whole tracheas from nontransplanted mice were homogenized in 200
 l of 5% TCA buffer. After centrifugation, supernatant fractions were ex-
tracted with water-saturated ether, followed by heating to remove the resid-
ual ether. Samples were diluted twice with phosphate buffer and assayed for
cGMP content according to the manufacturer’s instructions. Values are in-
dicated as picomoles per trachea.
EMSA. There are two putative regulatory binding sites of NF- B in the
upstream (distal) and downstream (proximal) regions of the iNOS promoter
(available from GenBank/EMBL/DDBJ under accession no. L09126; refer-
ence 21) recognized as NF- Bu (GGGATTTTCC;  971 to  962 bp) and
NF- Bd (GGGACTCTCC;  85 to  76 bp). To generate oligonucleotide
probes containing binding sites for NF- Bu and NF- Bd, consensus se-
quences (NF- Bu, 5 -TGCTAGGGGGATTTTCCCTCTCTCTGT-3 ;
NF- Bd, 5  CCAACTGGGGACTCTCCCTTTGGGAACA-3 ) were
prepared by Invitrogen. Gel shift assays were performed on nuclear extracts
prepared from tissue samples, as previously described (35). Probes were 5 -
labeled with  -[32P]ATP (3,000 Ci/mmol) using T4 polynucleotide kinase
(Promega). 5  g of extracted nuclear proteins were incubated with 0.1 ng
32P-labeled DNA for 20 min at room temperature in 10  l binding buffer
containing 1  g poly(dI-dC). To characterize the proteins involved in the
binding to the site of NF- B, supershift assays were performed using 4  g of
one of the following antibodies: p50, p65, RelB, c-Rel, or p52 (Santa Cruz
Biotechnology, Inc.). These antibodies were preincubated with the nuclear
extract mixture for 60 min at room temperature before the binding reaction.
The samples were electrophoresed on 6% nondenaturing polyacrylamide/
bisacrylamide gels (DNA retardation gel; Invitrogen) at room temperature
for 1 h at 100 V. Competition experiments were performed by adding a
100-fold molar excess of either unlabeled NF- Bu or NF- Bd probes.
Statistics. Data are expressed as mean   SEM. All statistical comparisons
were performed using a commercially available statistical package for the
Macintosh personal computer (Stat View-J 5.0; SAS Institute). One-way
analysis of variance and the Fisher’s posthoc test were used to compare con-
ditions between groups. Differences of P   0.05 were considered significant.
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